GFAP and Alzheimer disease: In the human brain, a decrease in both GFAP and MHC class II receptors was also observed by immunostaining in the temporal cortex of aged AD subjects (>80 years) compared with younger AD subjects (<80 years; Hoozemans et al., 2010).